Triptorelin: structure, approvals, trials and status

Triptorelin is a synthetic GnRH agonist peptide; this guide covers its FDA approvals, the trials behind them and its label warnings, as of November 17, 2026.

Complete guide6 min read

Key takeaway

Triptorelin is a synthetic ten-unit peptide and a GnRH agonist. FDA first approved it in 2000 as Trelstar. Its labels cover advanced prostate cancer and central precocious puberty in children 2 years and older. In the pediatric trial behind Triptodur, 41 of 44 children reached prepubertal LH levels at month 6. Neither label carries a boxed warning.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“FDA first approved triptorelin on June 15, 2000, as Trelstar.” (this article)
ClassReproductive hormones
Body systemsReproductive system
Studies cited3 in this article · 3 across 1 article on Triptorelin
Related productsResearch peptide catalog

Triptorelin is a lab-made version of gonadotropin-releasing hormone (GnRH), the brain signal that starts sex hormone production. This guide covers its structure, how it works, what FDA approved it for, the key trials and what its labels warn about. Sources were checked on November 17, 2026.

Quick answer: Triptorelin is a prescription peptide drug that copies GnRH. It briefly raises, then suppresses, the pituitary hormones that drive the testes and ovaries. That lowers testosterone and estrogen. Trelstar is labeled for advanced prostate cancer, and Triptodur for early puberty.

Vitrapep does not sell triptorelin; this page is a reference summary of published research and regulatory information. It is not medical advice.

What is triptorelin?

Triptorelin is a synthetic peptide. The Trelstar label calls it “a synthetic decapeptide agonist analog of gonadotropin releasing hormone (GnRH)” (Trelstar label). Decapeptide means a chain of ten amino acids.

PubChem gives its sequence as pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 (PubChem CID 25074470). The sixth unit is D-tryptophan, the mirror-image form of tryptophan. PubChem lists the synonym (D-Trp6)-GnRH for this reason. Its formula is C64H82N18O13 and its molecular weight is 1311.4 g/mol. Both US products contain the pamoate salt.

FDA first approved triptorelin on June 15, 2000, as Trelstar. Drugs@FDA lists it under NDA 020715 (Drugs@FDA). FDA approved Triptodur on June 29, 2017, under NDA 208956 (Drugs@FDA). For background, see our overview of peptide hormones.

Table 1

Triptorelin: key facts

Fact Detail
Structure Synthetic peptide of ten units with a D-tryptophan at position 6 and an amide end
Class GnRH agonist
Molecular formula C64H82N18O13 (PubChem)
Molecular weight 1311.4 g/mol (PubChem)
First FDA approval June 15, 2000 (Trelstar, NDA 020715)
Approved brands Trelstar, Triptodur

How does triptorelin work?

Natural GnRH travels from the brain to the pituitary gland. There it triggers the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These drive the testes and ovaries to make sex hormones. Our gonadorelin guide covers natural GnRH.

Triptorelin binds the same pituitary receptors. The Trelstar label reports cell and animal data on its strength. In lab tests, it was more active than native GnRH at releasing LH and binding pituitary receptors. In animals, it showed higher LH- and FSH-releasing activity than native GnRH.

In people, the label describes two phases. At first, LH, FSH, testosterone and estradiol rise briefly. With sustained exposure, LH and FSH secretion falls, and testosterone drops to the castrate range. The label says these effects are generally reversible after therapy stops. The early rise is why the Trelstar label carries a “Tumor Flare” warning.

What is triptorelin approved for?

Approved uses are set product by product, following section 1 of each label.

  • Trelstar: “TRELSTAR is indicated for the treatment of advanced prostate cancer.”
  • Triptodur: “the treatment of pediatric patients 2 years of age and older with central precocious puberty” (Triptodur label).

Central precocious puberty is puberty that starts early because the brain’s GnRH signal switches on early. Other GnRH agonists are covered in our guides to leuprolide and goserelin.

What did the key trials of triptorelin show?

Both trials below enrolled people, so these are human data.

Prostate cancer, 2003. A randomized trial compared triptorelin with leuprolide in 284 men with advanced prostate cancer. There were 140 men on triptorelin and 144 on leuprolide. The primary endpoint was reaching and keeping castrate testosterone levels over 9 months. Cumulative castration maintenance was 96.2% with triptorelin and 91.2% with leuprolide, which the authors judged equivalent. At day 29, fewer men on triptorelin were castrate: 91.2% versus 99.3%. Survival at 9 months was 97.0% versus 90.5% (P = 0.033). Both drugs were well tolerated (Heyns et al., 2003).

Central precocious puberty, 2016. A Phase 3, single-group trial enrolled 44 untreated children, 39 girls and 5 boys, at 18 centers (NCT01467882). The primary endpoint was LH suppression to prepubertal levels at month 6. In all, 41 children (93.2%) met it. No unexpected drug-related adverse events were reported (Klein et al., 2016). There was no comparison group. The Triptodur label reports the same 41 of 44 result.

What side effects does the triptorelin label list?

Neither label carries a boxed warning. The most common adverse reactions differ by product:

  • Trelstar: the label gives a list for each version, each at 5% or more. Hot flushes lead every list. Others include skeletal pain, headache, impotence or erectile dysfunction, leg edema, leg pain and testicular atrophy.
  • Triptodur: at 4.5% or more, injection site reactions, menstrual (vaginal) bleeding, hot flush, headache, cough and several infections.

Trelstar warnings cover hypersensitivity reactions, including reported anaphylactic shock and angioedema. They also cover tumor flare, metabolic changes, cardiovascular disease, convulsions, severe skin reactions, QT prolongation and harm to a fetus. Triptodur warnings cover the early hormone rise, psychiatric events, convulsions, severe skin reactions and pseudotumor cerebri, raised pressure around the brain.

What is the regulatory status of triptorelin, and is it used in research?

Triptorelin is a prescription drug. On October 20, 2010, FDA notified makers of GnRH agonists of new safety information for labeling. It covered diabetes and certain cardiovascular diseases: heart attack, sudden cardiac death and stroke. The agreed text says the risk “appears low based on the reported odds ratios” (FDA, 2011).

On July 1, 2022, FDA added a pseudotumor cerebri warning to GnRH agonists for central precocious puberty, including Triptodur. FDA found six cases supporting a plausible link, all in birth-assigned females aged 5 to 12 (FDA, 2022).

In sport, WADA’s 2026 Prohibited List names triptorelin under S2.2.1, “Testosterone-stimulating peptides in males.” S2 substances are prohibited at all times, in and out of competition. Athletes should check with their anti-doping organization. See our guide to the 2026 WADA list.

Triptorelin also appears in animal research. One study gave peripubertal female rats either triptorelin or the GnRH antagonist cetrorelix. Both delayed puberty. Only cetrorelix significantly reduced cortical bone measures; triptorelin values fell between the cetrorelix and control groups (Roth et al., 2005). These are rat data and do not show an effect in people. See our cetrorelix guide and what research use only means.

Frequently asked questions about triptorelin

Is triptorelin the same as Trelstar?

Triptorelin is the active ingredient. Trelstar was its first FDA-approved brand, in 2000. Triptodur, approved in 2017, is a second triptorelin product.

How is triptorelin different from leuprolide?

Both are GnRH agonists. Triptorelin has ten units with D-tryptophan at position 6. Leuprolide has nine, with D-leucine at that position. A 2003 trial found equivalent castration maintenance.

Is triptorelin used in children?

Triptodur is labeled for central precocious puberty in pediatric patients 2 years of age and older. Trelstar is labeled for advanced prostate cancer.

Is triptorelin banned in sport?

WADA’s 2026 list names triptorelin under S2.2.1, testosterone-stimulating peptides in males. S2 substances are prohibited at all times.

Does triptorelin have a boxed warning?

No. Warnings include hypersensitivity, tumor flare, metabolic and cardiovascular risks, and pseudotumor cerebri in children.

What to know now

  • What it is: a synthetic ten-unit GnRH agonist peptide with D-tryptophan at position 6.
  • Approval: first FDA approval June 15, 2000, as Trelstar; Triptodur followed in 2017.
  • Labeled uses: advanced prostate cancer and central precocious puberty.
  • Evidence: human trials in prostate cancer and central precocious puberty.
  • Safety: no boxed warning; FDA class actions in 2010 and 2022.
  • Sport: WADA prohibits triptorelin in males at all times.

What we’re watching

Results of LIBELULA, a Phase 3 trial of Debio 4326, an investigational longer-acting triptorelin formulation for central precocious puberty (NCT06129539). The registry lists 56 enrolled and a primary completion date of October 9, 2026. Also WADA’s 2027 Prohibited List, which takes effect on January 1, 2027. Our degarelix guide covers a GnRH antagonist.

More for reproductive system

All 12 compounds for reproductive system

Sources: Verity Pharmaceuticals Inc 2026, TRELSTAR (triptorelin pamoate) prescribing information; Azurity Pharmaceuticals 2025, TRIPTODUR (triptorelin) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: Trelstar (triptorelin pamoate), Drugs@FDA: Trelstar (triptorelin pamoate), NDA 020715; U.S. Food and Drug Administration. Drugs@FDA: Triptodur (triptorelin pamoate), Drugs@FDA: Triptodur (triptorelin pamoate), NDA 208956; National Center for Biotechnology Information. PubChem compound summary for CID 25074470, PubChem compound summary for CID 25074470, triptorelin; Heyns 2003, BJU International, 92; Klein 2016, Journal of Pediatric Endocrinology and Metabolism, 29; U.S. Food and Drug Administration 2011; U.S. Food and Drug Administration 2022, Risk of pseudotumor cerebri added to labeling for gonadotropin-releasing hormone agonists; World Anti-Doping Agency 2025, World Anti-Doping Code International Standard: Prohibited List 2026; Roth 2005, Experimental and Clinical Endocrinology & Diabetes, 113; Debiopharm International SA 2023. All 12 citations

Back to the research library

References

  1. Verity Pharmaceuticals Inc. (2026). TRELSTAR (triptorelin pamoate) prescribing information (revised June 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3
  2. Azurity Pharmaceuticals, Inc. (2025). TRIPTODUR (triptorelin) prescribing information (revised September 2025). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f41380e7-b830-432d-a5f5-a872932f107e
  3. U.S. Food and Drug Administration. Drugs@FDA: Trelstar (triptorelin pamoate), NDA 020715. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020715
  4. U.S. Food and Drug Administration. Drugs@FDA: Triptodur (triptorelin pamoate), NDA 208956. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208956
  5. National Center for Biotechnology Information. PubChem compound summary for CID 25074470, triptorelin. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/25074470
  6. Heyns, C. F., Simonin, M. P., Grosgurin, P., Schall, R., Porchet, H. C., & South African Triptorelin Study Group. (2003). Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU International, 92(3), 226–231. https://doi.org/10.1046/j.1464-410x.2003.04308.x
  7. Klein, K., Yang, J., Aisenberg, J., Wright, N., Kaplowitz, P., Lahlou, N., Linares, J., Lundström, E., Purcea, D., & Cassorla, F. (2016). Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. Journal of Pediatric Endocrinology and Metabolism, 29(11), 1241–1248. https://doi.org/10.1515/jpem-2015-0376 (ClinicalTrials.gov ID NCT01467882)
  8. U.S. Food and Drug Administration. (2011, January 14). Supplement approval letter, NDA 021088/S-025, citing FDA’s October 20, 2010 GnRH agonist safety notification. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021088s025ltr.pdf
  9. U.S. Food and Drug Administration. (2022, July 1). Risk of pseudotumor cerebri added to labeling for gonadotropin-releasing hormone agonists. https://www.fda.gov/media/159663/download
  10. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/en/prohibited-list
  11. Roth, C. L., Neu, C., Jarry, H., & Schoenau, E. (2005). Different effects of agonistic vs. antagonistic GnRH-analogues (triptorelin vs. cetrorelix) on bone modeling and remodeling in peripubertal female rats. Experimental and Clinical Endocrinology & Diabetes, 113(8), 451–456. https://doi.org/10.1055/s-2005-865710
  12. Debiopharm International SA. (2023). LIBELULA: A study to assess the efficacy, safety, and pharmacokinetics of Debio 4326 in pediatric participants with central precocious puberty (ClinicalTrials.gov ID NCT06129539). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT06129539